Findings

What do systematic reviews say?

42 questions · 46 findings · 10 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 6.5%GRADE not reported 4 · 8.7%Very low 5 · 10.9%Low 11 · 23.9%Moderate 18 · 39.1%High 5 · 10.9%

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 0.79 [0.64, 0.99]
1 study · 517 participants
Low

IRI with fluoropyrimidines vs single agent IRI

Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer

IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).

1 finding from 1 review

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
HR 0.68 [0.53, 0.83]
3 studies · 600 participants
Moderate